- Home
- ECBK vs VERU Comparison
ECBK vs VERU Comparison
Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | VERU |
|---|---|---|
| Founded | 1919 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 39.8M |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | ECBK | VERU |
|---|---|---|
| Price | $17.40 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 14.0K | ★ 109.7K |
| Earning Date | 02-04-2026 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.95 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $29,860,000.00 | $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.49 | ★ N/A |
| Revenue Growth | 20.84 | ★ 337.24 |
| 52 Week Low | $12.56 | $2.11 |
| 52 Week High | $17.75 | $14.20 |
Technical Indicators
Market Signals| Indicator | ECBK | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 41.85 |
| Support Level | $16.66 | $2.33 |
| Resistance Level | $17.55 | $2.63 |
| Average True Range (ATR) | 0.34 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 94.95 | 29.71 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.